Microscopic Colitis After Fecal Microbiota Transplant by Fasullo, Matthew J. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2017-07-19 
Microscopic Colitis After Fecal Microbiota Transplant 
Matthew J. Fasullo 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Digestive System Diseases Commons, Gastroenterology Commons, and the Pathological 
Conditions, Signs and Symptoms Commons 
Repository Citation 
Fasullo MJ, Al-Azzawi Y, Abergel J. (2017). Microscopic Colitis After Fecal Microbiota Transplant. Open 
Access Articles. https://doi.org/10.14309/crj.2017.87. Retrieved from 
https://escholarship.umassmed.edu/oapubs/3206 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
CASE REPORT | COLON
Microscopic Colitis After Fecal Microbiota Transplant
Matthew J. Fasullo, DO1, Yasir Al-Azzawi, MD2, and Jeffrey Abergel, MD3
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2Department of Gastroenterology, University of Massachusetts Medical Center, Worcester, MA
3Department of Gastroenterology, Staten Island University Hospital, Staten Island, NY
ABSTRACT
Microscopic colitis (MC) is an inﬂammatory condition of the large bowel that is associated with chronic, non-
bloody diarrhea. Colonoscopy usually demonstrates normal mucosa, while tissue biopsy reveals intraepithe-
lial lymphocytes or a subepithelial collagen band. Although no speciﬁc antibody has been discovered, MC
is associated with several autoimmune disorders such as celiac disease, Hashimoto’s thyroiditis, and rheu-
matoid arthritis. There are only a small number of case reports documenting possible hereditary MC
cases, but up to 12% of patients with MC have a family history of inﬂammatory bowel disease. Other
associations include proton pump inhibitor use, cigarette smoking, HLA-DQ2/86, and possibly some gastro-
intestinal infections.
INTRODUCTION
Microscopic colitis (MC) causes chronic diarrhea, abdominal cramping, nausea, anxiety, and weight loss.
Epidemiologic studies demonstrate that MC is a more common cause of diarrhea than previously shown,
affecting approximately 5 of every 100,000 people per year, with a mean age at diagnosis of 65 years and a
female preponderance.1,2 Several medications, autoimmune diseases, infections, and toxins have been associ-
ated with MC. Physical examination and colonoscopy are typically unremarkable.3 The diagnosis of MC can
only be made on the basis of abnormalities seen on colonic biopsies. Fecal microbiota transplant (FMT), on the
other hand, is the reconstitution of normal colonic ﬂora by a stool transplant from a healthy donor to an indi-
vidual infected with Clostridium difﬁcile.
CASE REPORT
A 39-year-old woman with a past medical history signiﬁcant for depression and recurrentClostridium difﬁcile infec-
tion presented with 2 weeks of profuse, watery diarrhea. She presented with similar symptoms 6 months prior, at
which time she was found to have a positive stool C. difﬁcile antigen. Over the next 10 weeks she was started on a
succession of treatments (ie, metronidazole, followed by oral vancomycin, and then ﬁdaxomicin) without symptom
resolution. Biopsies from a colonoscopy were unremarkable (Figure 1). She underwent a FMT 4 weeks later and
experienced complete symptom resolution during the initial 6 weeks after FMT. Her symptoms then returned, and
she was again hospitalized.
The patient described a gradual onset of profuse, watery diarrhea over 2 weeks that peaked at 10 bowel move-
ments per day. She denied nausea, vomiting, fever, myalgias, dizziness, hematochezia, changes to her diet,
recent travel, drug or tobacco use, and sick contacts. Physical exam was signiﬁcant for an anxious-appearing,
thin woman with mild left and right lower abdominal tenderness. Initial laboratory data, including basic meta-
bolic proﬁle, complete blood count, liver function test, thyroid-stimulating hormone, C-reactive protein, and
fecal calprotectin were all within normal limits. Additional tests, including anti-Saccharomices cerevisiae and a
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celiac disease panel, were negative. Infectious workup for
C. difﬁcile, human immunodeﬁciency virus, Escherichia coli,
salmonella, shigella, campylobacter, hepatitis panel, and
fecal leukocytes was negative. Abdominal imaging, includ-
ing ultrasound and computed tomography scan, was nega-
tive. Biopsies from a repeat colonoscopy revealed increased
intraepithelial lymphocytes in the colonic epithelial layer and
increased numbers of subepithelial chronic inﬂammatory
cells consistent with lymphocytic colitis (LC) (Figure 2). The
patient was promptly started on budesonide therapy, which
resulted in a signiﬁcant reduction in symptoms. She was sub-
sequently discharged 2 days later and was able to return to
work the next week.
DISCUSSION
MC is an inﬂammatory condition of the large bowel that is
associated with chronic, nonbloody diarrhea with a grossly
normal-appearing colonoscopy, and it is diagnosed by tissue
biopsy. MC can be further classiﬁed into 2 distinct classes: LC
and collagenous colitis (CC). The histopathological criteria
for CC include a thickened subepithelial collagen layer of at
least 10 mm, inﬂammation in the lamina propria with lympho-
cytes and plasma cells, and epithelial damage. The criteria for
LC is a density of at least 20 intraepithelial lymphocytes per
100 surface epithelial cells, epithelial damage, and a subepi-
thelial collagen layer of less than 10 mm.4 While the etiology
remains obscure, the most common theories suggest that
MC results from immune system activation in the colonic mu-
cosa after exposure to antigenic factors, including toxins,
infections, and medications. Commonly reported associations
include autoimmune-based disorders such as celiac disease,
thyroid disease, and rheumatoid arthritis, although no speciﬁc
antibody has yet been associated with MC. There are a small
number of case reports documenting cases of hereditary MC,
but up to 12% of patients with MC have a family history of
inﬂammatory bowel disease.5 Other potential associations
include the use of proton pump inhibitors, cigarette smok-
ing, and HLA-DQ2/8, and some case reports document
newly diagnosed MC after gastrointestinal infection with C.
difﬁcile, Yersinia species, and Campylobacter species.6-8
The diagnosis of MC often occurs after an extensive
workup for alternative causes of diarrhea. Withdrawal of
toxic agents and drugs is required when MC began as a
consequence of its use. While antidiarrheal agents are typi-
cally used, budesonide is the only drug proven to be effec-
tive in randomized, placebo-controlled trials, and it is
currently the standard treatment for MC.
We describe a previously healthy 39-year-old woman present-
ing with new microscopic colitis after FMT for recurrent C.
difﬁcile colitis. We postulate that gut dysbiosis caused by the
incorporation of a foreign microbiome resulted in a dysregu-
lated immune response. We postulate that this caused che-
motaxis of lymphocytes to the affected area as well as a spike
in bacterial metabolite production.9 While FMT is rapidly
being incorporated into clinical practice, much is still
unknown regarding the stool donor protocol as well as com-
plications of the therapy. The literature for reported compli-
cations of FMT include bloating, diarrhea, constipation,
perforation, and bacteremia, as well as a few reports docu-
menting adverse reactions including cancers.10 Other studies
have described histologic ﬁndings consistent with MC on
colonoscopic biopsies taken at the time of FMT, suggesting
its pathogenesis may be associated with C. difﬁcile rather
than FMT.11 Biopsies from our patient, however, were nega-
tive for MC prior to initiation of FMT. We hope to bring atten-
tion to a potential gap in knowledge regarding adverse
effects of FMT, and to suggest pre-FMT screening for MC
during donor analysis.
Figure 1. Normal colonic mucosa prior to FMT. Figure 2. Abnormal colonic mucosa consistent with lymphocytic colitis
showing >20 intraepithelial lymphocytes per 100 surface epithelial
cells.
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